Lymphoma & CLL Trials

The emerging role of MRD in the treatment of chronic lymphocytic leukemia

In this review, we summarize the role of MRD in the treatment of CLL, including methods of detection, clinical data on MRD...

Update on CLL induction therapy

An interview with Astrid Pavlovsky, Fundaleu CHP, Buenos Aires, AR, on the first-line treatment of chronic lymphocytic leukemia (CLL).

5-year outcomes of axicabtagene ciloleucel in adults with refractory LBCL: ZUMA-1 trial

Here, we summarize the article by Neelapu et al. on the 5-year outcomes of axicabtagene ciloleucel in adult...

Educational theme | Tumor intrinsic resistance mechanisms to CAR T-cell therapy in lymphomas

Here, we review tumor intrinsic resistance mechanisms to anti-CD19 CAR T-cell therapy in B-cell lymphomas...

Lisocabtagene maraleucel receives EC approval for the treatment of adult patients with R/R LBCL after one prior therapy

On May 3, 2023, it was announced that lisocabtagene maraleucel has received EC...

Lisocabtagene maraleucel as second-line therapy for adult patients with LBCL: Primary analysis of the phase III TRANSFORM trial

Primary analysis of the phase III TRANSFORM trial indicates that...

What are the key updates to the NCCN guidelines® for CLL/SLL?

Following recent changes to the NCCN guidelines®, the Lymphoma Hub was pleased to speak to Deborah Stephens, Huntsman Cancer Institute,...

Zanubrutinib receives FDA approval for CLL and SLL

The U.S. Food and Drug Administration (FDA) has granted approval to zanubrutinib for the treatment of adult patients with chronic lymphocytic...